{"For": [0], "patients": [1, 130], "with": [2, 80, 120, 131, 153], "metastatic": [3], "non-small-cell": [4], "lung": [5], "cancer": [6], "(mNSCLC),": [7], "the": [8, 26, 32, 42, 49, 90, 93, 108, 113, 121, 144, 158, 163], "last": [9], "decade": [10], "has": [11, 18, 97], "been": [12], "characterized": [13], "by": [14], "critical": [15], "progress": [16, 96], "that": [17], "contributed": [19], "to": [20, 63], "substantially": [21], "improved": [22], "survival.": [23], "In": [24], "particular,": [25], "development": [27, 75], "of": [28, 52, 70, 76, 110, 123, 147], "specific": [29], "antibodies": [30], "against": [31], "programmed": [33, 37], "death": [34], "(PD-1)": [35], "receptor,": [36], "death-ligand": [38], "1": [39], "(PD-L1),": [40], "and": [41, 82], "cytotoxic": [43], "T-lymphocyte-associated": [44], "protein": [45], "4": [46], "receptor": [47], "in": [48, 55, 58, 89, 102, 116, 138, 150, 156], "therapeutic": [50], "strategy": [51], "mNSCLC": [53, 124, 132, 151], "either": [54], "first-": [56], "or": [57, 135], "second-line": [59, 91], "settings": [60, 104], "have": [61], "led": [62], "unprecedented": [64], "prolonged": [65], "survival": [66], "for": [67, 162], "a": [68], "proportion": [69], "these": [71], "patients.": [72], "Although": [73], "clinical": [74, 114], "immune": [77], "checkpoint": [78], "inhibitors": [79], "anti-PD-1": [81], "PD-L1": [83, 136], "therapies": [84], "largely": [85], "began": [86], "as": [87, 105, 107], "monotherapy": [88], "setting,": [92], "more": [94], "recent": [95], "shifted": [98], "toward": [99], "combination": [100], "approaches": [101], "first-line": [103, 139, 148], "well": [106], "integration": [109], "immunotherapy": [111, 149], "into": [112], "paradigm": [115], "earlier": [117], "stages.": [118], "Today,": [119], "exception": [122], "harboring": [125], "targetable": [126], "oncogenes,": [127], "nearly": [128], "all": [129], "receive": [133], "PD-1": [134], "therapy": [137], "settings.": [140], "Here": [141], "we": [142], "report": [143], "current": [145, 154], "status": [146], "together": [152], "challenges": [155], "selecting": [157], "best": [159], "immunotherapeutic": [160], "approach": [161], "individual": [164], "patient.": [165]}